News Jemperli label extended to include rectal cancer GSK's PD-1 inhibitor Jemperli has been cleared by the FDA as the first pre-operative cancer immunotherapy for rectal cancer.
News Trodelvy gets EU nod for first-line triple-neg breast cancer A new EC authorisation expands Gilead's market for triple-negative breast cancer ADC Trodelvy.
News GSK to file Jemperli for rectal cancer after phase 3 readout GSK's pivotal AZUR-1 trial of Jemperli monotherapy to delay or eliminate surgery in pre-operative rectal cancer has delivered a positive result.
Oncology ASCO 2026: A potential functional cure in endometrial cancer... For GSK, ASCO 2026 was about long-term follow-up data, with new data from ongoing trials of Jemperli and Blenrep.
News GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.
News GSK unit and AnaptysBio trade lawsuits over Jemperli A spat between GSK/Tesaro and AnaptysBio over cancer drug Jemperli has escalated into litigation, with both parties claiming breach of contract.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.